Pia Kvistborg
Overview
Explore the profile of Pia Kvistborg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
8954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dopler A, Alkan F, Malka Y, van der Kammen R, Hoefakker K, Taranto D, et al.
Cell
. 2024 Oct;
187(24):6981-6993.e23.
PMID: 39437780
Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of...
2.
Gangaev A, van Sleen Y, Brandhorst N, Hoefakker K, Prajapati B, Singh A, et al.
Front Immunol
. 2024 Sep;
15:1447555.
PMID: 39257577
Introduction: Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains...
3.
Isaeva O, Ketelaars S, Kvistborg P
Front Immunol
. 2022 May;
13:891524.
PMID: 35572563
Since the start of the COVID-19 pandemic, mutations have led to the emergence of new SARS-CoV-2 variants, and some of these have become prominent or dominant variants of concern. This...
4.
Oosting S, van der Veldt A, Fehrmann R, GeurtsvanKessel C, van Binnendijk R, Dingemans A, et al.
Lancet Oncol
. 2022 Apr;
23(7):833-835.
PMID: 35483383
No abstract available.
5.
Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M, et al.
Eur J Immunol
. 2021 Dec;
51(12):2708-3145.
PMID: 34910301
The third edition of Flow Cytometry Guidelines provides the key aspects to consider when performing flow cytometry experiments and includes comprehensive sections describing phenotypes and functional assays of all major...
6.
Oosting S, van der Veldt A, GeurtsvanKessel C, Fehrmann R, van Binnendijk R, Dingemans A, et al.
Lancet Oncol
. 2021 Nov;
22(12):1681-1691.
PMID: 34767759
Background: Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for...
7.
Gangaev A, Rozeman E, Rohaan M, Isaeva O, Philips D, Patiwael S, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(43).
PMID: 34670835
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized the treatment of melanoma patients. Based on early studies addressing the...
8.
Nagler A, Kalaora S, Barbolin C, Gangaev A, Ketelaars S, Alon M, et al.
Cell Rep
. 2021 Jun;
35(13):109305.
PMID: 34166618
The human leukocyte antigen (HLA)-bound viral antigens serve as an immunological signature that can be selectively recognized by T cells. As viruses evolve by acquiring mutations, it is essential to...
9.
Gangaev A, Ketelaars S, Isaeva O, Patiwael S, Dopler A, Hoefakker K, et al.
Nat Commun
. 2021 May;
12(1):2593.
PMID: 33972535
The COVID-19 pandemic caused by SARS-CoV-2 is a continuous challenge worldwide, and there is an urgent need to map the landscape of immunogenic and immunodominant epitopes recognized by CD8 T...
10.
Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al.
Nature
. 2021 Mar;
592(7852):138-143.
PMID: 33731925
A variety of species of bacteria are known to colonize human tumours, proliferate within them and modulate immune function, which ultimately affects the survival of patients with cancer and their...